Matt Kaeberlein to present at the 8th Aging Research & Drug Discovery Meeting 2021

Thursday, July 1, 2021 — Matt Kaeberlein, PhD, will present the latest research on the topic 100,000 longevity interventions per year: How robotics and AI can get us there in 6 months at the worlds’ largest annual Aging Research and Drug Discovery conference (8th ARDD). Dr. Matt Kaeberlein is a Professor of Laboratory Medicine and Pathology at the University of Washington (UW) School of Medicine, with Adjunct appointments in Genome Sciences and Oral Health Sciences.

“A major bottleneck in translational geroscience has been an inability to rapidly screen and identify new interventions, particularly combinations of two, three, four or more small molecules, that are able to robustly increase lifespan and healthspan in preclinical models. Using C. elegans, we are overcoming this obstacle by combining the WormBot with Artificial Intelligence to allow fully automated, high-throughput lifespan analysis with healthspan metrics. Scaling up capacity from where we are today by 20-fold will allow for testing of up to 100,000 longevity interventions per year.” said Matt Kaeberlein, PhD, Professor of Laboratory Medicine and Pathology at the University of Washington.

Dr. Kaeberlein’s research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published more than 200 scientific papers and has been recognized by several prestigious awards including young investigator awards from the Ellison Medical Foundation and the Alzheimer’s Association, the Vincent Cristofalo Rising Start in Aging Research Award, the Murdock Trust Award, the NIA Nathan W. Shock Award, and the Robert W. Kleemeier Award for outstanding research in the field of gerontology from the Gerontological Society of America (GSA).

Dr. Kaeberlein has been awarded Fellow status with the American Association for the Advancement of Science (AAAS), the American Aging Association (AGE), and the GSA. Dr. Kaeberlein is currently the CEO and Chair of AGE, Past-President of AGE, has served on the Board of Directors for the Federation of American Societies for Experimental Biology (FASEB) and AGE, and has served as Biological Sciences Chair and on Council for GSA. Dr. Kaeberlein is the founding Director of the University of Washington (UW) Healthy Aging and Longevity Research Institute, the Director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging at UW, Director of the Biological Mechanisms of Healthy Aging Training Program, and founder and co-Director of the Dog Aging Project.

The conference proceedings of the ARDD are commonly published in peer-reviewed journals with the talks openly available at

http://www.

org

. Please review the conference proceedings for 2019 and 2020.

“Aging is emerging as a druggable condition with multiple pharmaceuticals able to alter the pace of aging in model organisms. The ARDD brings together all levels of the field to discuss the most pressing obstacles in our attempt to find efficacious interventions and molecules to target aging. The 2021 conference is the best yet with top level speakers from around the globe. I’m extremely excited to be able to meet them in person at the University of Copenhagen in late summer.”, said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.

“Aging research is growing faster than ever on both academia and industry fronts. The ARDD meeting unites experts from different fields and backgrounds, sharing with us their latest groundbreaking research and developments. Our last ARDD meeting took place online and was a great success. This year’s event will be a hybrid meeting with virtual and in-person attendees. I am particularly excited that being part of the ARDD 2021 meeting will provide an amazing opportunity for young scientists presenting their own work as well as meeting the experts in the field.” said Daniela Bakula, Ph.D., University of Copenhagen

“Aging research is gaining traction in the biopharmaceutical industry. To my knowledge, 6 out of the top 30 pharmaceutical companies in the world prioritized aging research for early-stage discovery or therapeutic pipeline development and several companies employ artificial intelligence for this purpose. We organize the annual ARDD conference for eight years in a row and the level of interest in aging biomarkers and noticed exponential growth in registrations over the past two years”, said Alex Zhavoronkov, Ph.D., co-founder and CEO of Insilico Medicine, and the founder of Deep Longevity.

Building on the success of the ARDD conferences, the organizers developed the “Longevity Medicine” course series with some of the courses offered free of charge at Longevity.Degree covered in the recent Lanced Healthy Longevity paper titled Longevity medicine: upskilling the physicians of tomorrow.

About Aging Research for Drug Discovery Conference
At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we are expanding with a workshop specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems: aging. Our quest? To extend the healthy lifespan of everyone on the planet.

About Scheibye-Knudsen Lab
In the Scheibye-Knudsen lab we use in silico, in vitro and in vivo models to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.

About Deep Longevity
Deep Longevity has been acquired by Regent Pacific (SEHK:0575.HK), whose shares are listed on the Hong Kong Stock Exchange. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed “deep aging clocks” to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.

https:/

About Endurance RP (SEHK:0575.HK)
Endurance RP is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.

https:/

###